Spots Global Cancer Trial Database for esophagogastric cancer
Every month we try and update this database with for esophagogastric cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers | NCT02296671 | Esophagogastric... | Pemetrexed Oxaliplatin Leucovorin Fluorouracil Germline genoty... | 18 Years - | Washington University School of Medicine | |
| Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer | NCT02954536 | Esophageal Canc... Gastric Cancer | pembrolizumab trastuzumab capecitabine cisplatin Oxaliplatin 5-Fluorouracil | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors | NCT01803282 | Pancreatic Canc... Non-small Cell ... Esophagogastric... Colorectal Canc... Breast Cancer | Andecaliximab Gemcitabine Nab-paclitaxel Carboplatin Pemetrexed Leucovorin Oxaliplatin 5-FU Bevacizumab Irinotecan Paclitaxel | 18 Years - | Gilead Sciences | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas | NCT00215995 | Esophageal Canc... Gastric Cancer | Cisplatin Irinotecan ZD 1839 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing | NCT03133650 | Esophagogastric... Moderate to Sev... | WST 11-mediated... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Tooth Erosion in People With Esophagogastric Cancer | NCT05612048 | Esophagogastric... | Survey Intra-oral came... Optional Salvia... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer | NCT04757363 | Esophagogastric... HER2-Negative | regorafenib nivolumab FOLFOX chemothe... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer | NCT02954536 | Esophageal Canc... Gastric Cancer | pembrolizumab trastuzumab capecitabine cisplatin Oxaliplatin 5-Fluorouracil | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| A Study of Amivantamab in People With Esophagogastric Cancer | NCT05117931 | Esophagogastric... | Amivantamab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas | NCT00215995 | Esophageal Canc... Gastric Cancer | Cisplatin Irinotecan ZD 1839 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
